Latest Schizophrenia Treatments and the Future of Longevity for Patients

Schizophrenia is one of the most challenging psychiatric disorders of our time, affecting approximately 20 million people worldwide. But beyond the hallucinations, delusions, and cognitive symptoms that define the condition, there is a far less discussed crisis: people with schizophrenia die 15 to 20 years earlier than the general population — and in some studies, the gap is as wide as 28.5 years.

For decades, the mortality gap has been largely driven not by the psychiatric symptoms themselves, but by preventable physical health conditions — particularly cardiovascular disease, metabolic syndrome, and infections. Traditional antipsychotic medications, while effective at managing positive symptoms such as hallucinations, have often worsened the physical health picture through side effects including weight gain, diabetes, and metabolic disruption.

Now, however, a wave of groundbreaking treatments is emerging that could fundamentally change this equation — not just managing schizophrenia symptoms more effectively, but doing so with far fewer of the side effects that shorten lives.

The Life Expectancy Gap: A Hidden Health Crisis

According to a 2025 study published in Schizophrenia, patients with schizophrenia in a Romanian cohort died at a mean age of just 58.97 years — roughly 17 years earlier than the general population. The standardised mortality ratio was 1.58, meaning a 58% higher mortality risk overall.

Research from King’s Health Partners (2025) described this as a “hidden health crisis,” noting that the UK public vastly underestimates the impact — typically guessing the gap at just seven years, when the true figure is 15 to 20 years. Severe mental illness shortens lives more than diabetes, severe obesity, and even smoking.

The causes are well documented:

• Cardiovascular disease accounts for 40–50% of excess deaths in most studies (Frontiers in Psychiatry)
• Metabolic syndrome is up to four times more common in people with schizophrenia
• Infectious diseases, particularly pneumonia, contribute significantly — accounting for nearly 30% of clozapine-related deaths
• Suicide accounts for about 40% of unnatural deaths, though it represents a smaller portion of the total mortality gap than physical illness
• “Diagnostic overshadowing” — where physical symptoms are mistakenly attributed to the mental illness — means many physical conditions go undetected and untreated

As Professor Christoph Correll of the Zucker School of Medicine puts it: “This is not primarily due to schizophrenia itself, but to preventable and treatable causes associated with it.”

Cobenfy: The First New Approach in Over 70 Years

In September 2024, the FDA approved Cobenfy (xanomeline and trospium chloride) — the first antipsychotic to work through an entirely new mechanism of action since the 1950s. Instead of blocking dopamine D2 receptors like every other antipsychotic on the market, Cobenfy targets muscarinic acetylcholine receptors (M1 and M4) in the brain.

This distinction matters enormously for longevity. Traditional dopamine-blocking antipsychotics are directly linked to the metabolic and cardiovascular side effects that drive the mortality gap. Cobenfy, by operating through a completely different pathway, largely avoids these problems.

According to Wellcome Trust, Phase 3 trials found that Cobenfy:

• Achieved clinically meaningful reductions in positive symptoms (delusions, hallucinations)
• Improved negative symptoms — including lack of motivation, social withdrawal, and cognitive impairment — which current drugs rarely address
• Showed low incidence of weight gain, sedation, and abnormal motor movements — the very side effects that destroy physical health in schizophrenia patients

In the pivotal EMERGENT-2 trial, Cobenfy demonstrated a 9.6-point reduction in PANSS total score versus placebo (p<0.0001), with a moderate effect size (Cohen’s d = 0.61). The EMERGENT-3 trial confirmed these findings with an 8.4-point reduction.

As Bristol Myers Squibb CEO Chris Boerner stated: “After more than 30 years, there is now an entirely new pharmacological approach for schizophrenia — one that has the potential to change the treatment paradigm.”

Why This Matters for Longevity

The connection between Cobenfy’s mechanism and longevity improvement is straightforward. If the primary drivers of early death in schizophrenia are cardiovascular disease and metabolic syndrome — and if these conditions are significantly worsened by traditional antipsychotic side effects — then a treatment that avoids these side effects while maintaining symptom control could meaningfully extend life expectancy.

According to a 2026 review in CNS Drugs, Cobenfy’s approval “represents a significant milestone, establishing it as the first and only nondopaminergic antipsychotic approved for schizophrenia.” The same review notes that it addresses “all three domains of schizophrenia symptoms — positive, negative, and cognitive — a challenge that traditional antipsychotics have been unable to surmount.”

Additionally, the 2025 Nature study found that second-generation antipsychotics (SGAs) were associated with a 63% reduction in mortality risk compared to first-generation antipsychotics. Even more strikingly, SGA long-acting injectables reduced mortality risk by 81%. Cobenfy, with its superior metabolic profile, could push these benefits even further.

The Pipeline: What Comes Next

Cobenfy has opened the floodgates for a new generation of treatments. Here are the most promising developments in the pipeline:

Next-Generation Muscarinic Modulators

ML-007 (MapLight Therapeutics) employs a dual M1/M4 agonist mechanism similar to Cobenfy but with what the developers describe as a more “precision-matched” approach to managing peripheral side effects. The ZEPHYR Phase II study, initiated in July 2025, is enrolling approximately 300 patients with acute schizophrenia.

NBI-1117568 (Neurocrine Biosciences) is an oral M4 selective muscarinic agonist that entered Phase III trials in May 2025 for acute schizophrenia in adults.

Novel Dopamine-Targeting Approaches

Brilaroxazine (RP5063) by Reviva Pharmaceuticals is a multimodal modulator targeting serotonin and dopamine receptors. Its Phase II RECOVER trial met all primary and secondary endpoints, with a 1-year extension showing dose-dependent efficacy and a favourable safety profile with a 35% discontinuation rate.

LB-102 (LB Pharmaceuticals) has shown a “potentially class-leading tolerability profile” among dopamine D2/D3 antagonists, with differentiated activity across cognitive and negative symptom domains. Positive Phase II results were presented at the 2025 SIRS Congress in Chicago.

Digital Therapeutics

CT-155 (Boehringer Ingelheim) is a smartphone-based digital therapeutic targeting the negative symptoms of schizophrenia — the apathy, social withdrawal, and anhedonia that current medications struggle to treat. It received FDA Breakthrough Device Designation and is currently in Phase III trials (CONVOKE), the largest clinical trial ever evaluating a digital therapeutic in schizophrenia.

Precision Medicine: The SEAD1 Breakthrough

In March 2026, Northwestern University researchers published a landmark study in Neuron identifying a novel biomarker (Cacna2d1) in the cerebrospinal fluid of schizophrenia patients. They then created a synthetic peptide called SEAD1 that, when injected into mouse brains, corrected both abnormal brain circuit activity and behavioural problems linked to the disorder — without observable negative side effects.

Lead researcher Peter Penzes described it as potentially “almost like Ozempic for schizophrenia — an injection that you can give once a week.” The biomarker-therapeutic combination is revolutionary because it can identify a subset of patients most likely to respond, paving the way for true precision psychiatry.

How These Advances Could Improve Longevity

The implications for life expectancy are profound when we connect these treatment developments to the mortality data:

1. Reduced metabolic burden: Muscarinic agonists like Cobenfy avoid the weight gain, diabetes, and dyslipidæmia that drive cardiovascular mortality. If widely adopted, they could significantly reduce the 40–50% of excess deaths attributable to cardiovascular disease.
2. Better treatment adherence: Treatments with fewer debilitating side effects mean patients are more likely to stay on medication. The 2025 Romanian study found that longer duration of untreated psychosis and poor medication adherence were key drivers of early death.
3. Addressing negative symptoms: Social withdrawal, apathy, and cognitive impairment make patients less likely to exercise, eat well, attend medical appointments, or maintain social connections — all factors in premature mortality. Treatments like Cobenfy, CT-155, and SEAD1 directly target these symptoms.
4. Precision medicine: Biomarker-guided treatment means the right patients get the right drugs, reducing the trial-and-error prescribing that leaves many patients on ineffective or harmful medications for years.
5. Integrated care models: As Dr Correll emphasises, “Routine monitoring and treatment of cardiovascular risk factors should be standard, not optional.” Better psychiatric treatments free up clinical resources for the physical health monitoring that saves lives.

What Still Needs to Change

Breakthrough medications alone will not close the mortality gap. Experts identify several critical areas that must improve in parallel:

• Integrated physical and mental healthcare: Psychiatric patients need routine cardiovascular screening, metabolic monitoring, and cancer screening embedded within their care pathways
• Smoking cessation support: Smoking rates in schizophrenia are disproportionately high, and Dr Khan advocates integrating smoking-cessation programmes into routine psychiatric care rather than treating tobacco as “an afterthought”
• Reducing stigma: Diagnostic overshadowing — where doctors attribute physical symptoms to mental illness — remains a deadly problem that requires systemic cultural change within healthcare
• Long-acting injectable adoption: The 81% mortality risk reduction associated with SGA long-acting injectables suggests these should be offered far more widely
• Vaccination and infection prevention: Routine vaccination (pneumococcal, influenza, COVID-19) and prompt treatment of respiratory symptoms are essential, given that infections are a significant cause of death

The Future Outlook

We are at a genuine inflection point in schizophrenia treatment. For the first time in over seven decades, clinicians have access to a fundamentally new class of medication — and the pipeline is rich with further innovation. As Psychiatric Times puts it: “By shifting from dopamine antagonism to muscarinic modulation, we could be on the brink of a paradigm shift that extends far beyond schizophrenia treatment.”

The combination of metabolically safer medications, precision biomarkers, digital therapeutics targeting negative symptoms, and a growing recognition that physical health must be treated alongside psychiatric symptoms creates a realistic pathway to narrowing — and eventually closing — the longevity gap.

People living with schizophrenia deserve, as Professor Correll states, “not only symptom control, but the same chance at a long life span as well as health span as anyone else.” For the first time, the science is catching up to that aspiration.

Sources: This article draws on research published in Nature Schizophrenia, CNS Drugs, Frontiers in Psychiatry, JAMA Psychiatry, Annals of Medicine and Surgery, Neuron, the Wellcome Trust, Psychiatric Times, the FDA, Bristol Myers Squibb, and King’s Health Partners. All linked citations provide direct access to the original studies and reports.